Scale Arrives Faster Than Expected
Neuralink now has 21 participants enrolled in its clinical trials, the company disclosed this week. The figure represents a sharp acceleration in recruitment for a technology that performed its first human implant just over a year ago. Each participant carries a coin-sized device in their skull, threaded with electrodes thinner than human hair.
The company began its PRIME study (Precise Robotically Implanted Brain-Computer Interface) in 2024 after receiving FDA approval. The first participant, Noland Arbaugh, demonstrated control of a computer cursor and played online chess using only neural signals. A second participant followed months later. The jump to 21 suggests the screening, surgical, and post-operative protocols have matured beyond proof-of-concept.
What This Volume Means
Clinical trials in the BCI space typically move with geological patience. Safety reviews, surgical precision requirements, and the complexity of long-term neural recording have historically kept participant numbers low. Synchron, a competitor, has enrolled fewer than 10 participants in its U.S. trial since 2021. Blackrock Neurotech, with decades of academic collaboration, counts its human users in the dozens across all studies.
Neuralink’s enrollment pace signals both technical confidence and operational capacity. The company’s automated surgical robot can complete implantation in under two hours, a speed unmatched in the field. Volume at this stage allows for statistical patterns to emerge around signal stability, tissue response, and device longevity.
The Path From 21 to Thousands
The PRIME study targets people with quadriplegia, focusing on restoring digital autonomy. Early results emphasize cursor control, text input, and device operation. But the company’s longer ambition stretches toward broader neurological conditions and eventually elective augmentation.
Twenty-one is still small. The gap between clinical trial and widespread availability requires regulatory milestones that depend on safety data measured in years, not months. Yet the number establishes a baseline that didn’t exist before: human-scale data collection in a BCI system designed for manufacturability. If the devices perform consistently across this cohort, the argument for expanded trials strengthens.
The BCI industry watches these enrollments because they set the tempo for what comes next. Competitors will adjust timelines. Investors will recalibrate risk models. Regulatory agencies will gather comparative data. The distance between 21 and routine clinical use remains vast, but the company has closed the distance between prototype and repeatable procedure.